Clinical Trial Update: VS-6766+Abema+Fulv in Met HR+/HER- BC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating VS-6766 in combination with Abemaciclib and Fulvestrant for metastatic hormone receptor-positive, HER2-negative breast cancer; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Fulvestrant (fulvestrant)
• VS-6766 (VS-6766)

Snippet

Sponsor: Adrienne G. Waks | Conditions: Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING